Calculation of Platelet-rich Plasma Preparation Yield

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-30

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to determine 1) the consistency of platelet-rich plasma produced by several methods, and 2) whether the platelet content of platelet-rich plasma can be accurately estimated from a baseline CBC platelet count.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The SOLID Platelet Study

NCT03712618

Platelet Transfusion Refractoriness (PTR) Thrombocytopenia

TERMINATED PHASE2

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

NCT00102323

Thrombocytopenia Idiopathic Thrombocytopenic Purpura

COMPLETED PHASE3

Study for Validation of In-vitro Turbidometric Platelet Aggregation Assay Using Human Blood in Healthy Volunteers

NCT02071628

Validation of In-vitro Turbidometric Platelet Aggregation Assay

COMPLETED

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

NCT00102336

Thrombocytopenia Idiopathic Thrombocytopenic Purpura

COMPLETED PHASE3

Platelet Products Tested With the ThromboLUX® Platelet Quality Test

NCT02158416

Poor Platelet Transfusion Outcome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the first phase of this study a baseline CBC platelet count will be performed on each subject and then platelet-rich plasma (PRP) prepared from the same blood sample by six different methods. The platelet count will be measured in each PRP preparation and compared to the CBC platelet count to determine the platelet yield for each method.

In the second phase of the study a baseline CBC platelet count will be performed on each subject and then platelet-rich plasma (PRP) prepared from the same blood sample by six different methods. The CBC platelet count will be used to calculate the estimated platelet content of each sample/method based on the platelet yields determined in the first phase. The platelet count will be measured in each PRP preparation and compared to the estimated platelet content to determine the predictive accuracy for each method.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet-rich Plasma Production

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

venipuncture

blood draw for the purpose of determining the platelet concentration in PRP

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* English speaking

Exclusion Criteria

* platelet count \< 150,000
* platelet count \> 350,000
* History of blood disorder
* History of altered platelet function
* History of chemotherapy or radiation therapy

Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes